Two Democrats who have a chance to stamp their mark on Gov. Maura Healey’s $3.5 billion plan to reinvigorate the state’s business climate want the benefits to stretch beyond the Boston metropolitan area.
A new report from commercial real estate brokerage JLL says tenant demand in Greater Boston has fallen by nearly 40 percent this year.
It’s looking like the answer to the question of what to do with a piece of real estate is no longer just “convert it to life science space,” at least for a few years.
Massachusetts has a long history of birthing new technologies and new industries, only to see them pack up and leave for sunnier climes, from textiles to computers.
In its annual Industry Snapshot released Wednesday, the Massachusetts Biotechnology Council said the 82,496 jobs recorded last year represent 92 percent growth over the last 15 years.
For years, Massachusetts has been renowned as the best place in the world for the life sciences. To keep it that way, we must foster the growth of mini-biotech clusters statewide.
A California-based biotech company says it plans to build a 100,000-square-foot factory in Bedford to supply clinical trials of several drugs it is currently developing.
Somerville’s Inner Belt district checks many of the boxes that are in demand among commercial developers. And the 100-acre neighborhood is seeing signs it could transform under the weight of demand for life science space.
Greater Boston’s massive life science real estate boom largely bypassed Somerville and Charlestown in recent years as growing firms gravitated toward western suburbs instead.
As the office market in Greater Boston continues to suffer amidst the pandemic – with firms listing more than 2.7 million square feet of office sublease space in recent months – the region’s life-science sector remains red-hot, as biotech and pharmaceutical companies continue to sign major leases and relentlessly look to expand.
Worcester is hungry for more life science success after pads at the 46-acre Reactory biomanufacturing park were rapidly bought up by firms eager to exploit its relatively close connection to Kendall Square.
Major local life science landlord King Street Properties paid $4.7 million for a pair of sites at Devens, the former Army base emerging as a Central Massachusetts industrial hub.
Reading-based Berkeley Building Co. has begun construction of a new corporate headquarters for Genuity Science at 90 Canal St. in Boston.
Boston architecture firm SGA is expanding its life science practice with the acquisition of a Portland, Maine-based consultancy focused on biopharma research and development facilities.
Underscoring the strength of the life science industry powering developments in Cambridge, Worcester, Boston and beyond, the Massachusetts Biotechnology Council said that the Massachusetts biopharma industry raised $2.1 billion in venture capital investment in the first half of 2020.
In the wake of widespread pushback against earlier proposals, state transportation officials floated a new design Monday for a landmark Allston infrastructure project that they will consider alongside two other options as a key deadline approaches.
While investor activity in Massachusetts’ life sciences sector is generating new demand for tens of thousands of square feet in Cambridge, the state’s broader biopharmaceutical sector could emerge from the coronavirus pandemic weaker than some may assume.
The first tenant at a landmark Worcester biotech park has secured key city councilors’ support for an $11.5 million tax relief package that will enable the project to move forward.
Boston-based Samuels & Assoc. has begun demolition work to prepare for construction of 201 Brookline Ave., a 500,000-square-foot office-lab tower.
If we get hit with anything like what we have seen from afar in China, there will be major disruptions to every facet of life, including businesses.
